Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Brentuximab vedotin for CTCL

Christoph Blazejak • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Brentuximab vedotin

Christoph Blazejak, MD, Department of Dermatology HELIOS Klinikum Krefeld, Krefeld, Germany, outlines the use of the CD30-targeting antibody-drug conjugate brentuximab vedotin in the treatment of cutaneous T-cell lymphoma (CTCL), highlighting a response rate of around 60% and a median progression-free survival of around a year. Dr Blazejak also comments on the safety profile of brentuximab vedotin and on the impact of its approval on the CTCL treatment landscape. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals